Collegium Pharmaceutical’s (COLL) “Buy” Rating Reiterated at Jefferies Group
Collegium Pharmaceutical Inc. (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Group in a note issued to investors on Thursday.
Several other analysts have also recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, September 14th. Gabelli started coverage on Collegium Pharmaceutical in a research note on Tuesday, September 13th. They issued a “buy” rating and a $25.00 price target on the stock. Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. Finally, Piper Jaffray Cos. set a $23.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $27.60.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 12.82 on Thursday. Collegium Pharmaceutical has a 52-week low of $8.24 and a 52-week high of $30.58. The firm has a 50-day moving average of $10.61 and a 200 day moving average of $14.46. The company’s market capitalization is $301.63 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/collegium-pharmaceuticals-coll-buy-rating-reiterated-at-jefferies-group.html
Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. On average, analysts anticipate that Collegium Pharmaceutical will post ($3.86) EPS for the current year.
In other news, Director John A. Fallon acquired 2,375 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The shares were bought at an average cost of $10.59 per share, with a total value of $25,151.25. Following the acquisition, the director now owns 2,375 shares in the company, valued at approximately $25,151.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 37.93% of the stock is owned by company insiders.
Several institutional investors have recently made changes to their positions in COLL. Nationwide Fund Advisors raised its position in Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 3,665 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth $122,000. Royal Bank of Canada raised its stake in shares of Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 300 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth $143,000. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth $148,000. 62.13% of the stock is currently owned by institutional investors.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.